{"filing":{"accession_number":"0001213900-26-070380","cik":"0001892500","ticker":"CMND","company_name":"Clearmind Medicine Inc.","form":"6-K","filing_date":"2026-06-22","report_date":null,"primary_document":"ea0295429-6k_clearmind.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1892500/000121390026070380/ea0295429-6k_clearmind.htm"},"events":[{"id":12616,"run_id":11190,"accession_number":"0001213900-26-070380","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This press release announces the successful completion of Part A treatment for all 24 participants in Clearmind's Phase I/II clinical trial of CMND-100 for Alcohol Use Disorder. The company states it is \"currently assessing the dataset and, assuming results remain favorable, intends to initiate the next stage of the clinical program.\" This is a material clinical development milestone for a clinical-stage biotech company, but it is not a discrete earnings release (no financial results disclosed), nor does it fit other specific event categories. It represents a significant operational/clinical progress event that would affect a reasonable investor's assessment of the company's pipeline advancement.","company_name":"Clearmind Medicine Inc.","ticker":"CMND","filing_date":"2026-06-22","form":"6-K","submitted_at":null,"items":[{"id":9519,"accession_number":"0001213900-26-070380","item_number":"EX-99.1","item_title":"ea029542902ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces the successful completion of Part A treatment for all 24 participants in Clearmind's Phase I/II clinical trial of CMND-100 for Alcohol Use Disorder. The company states it is \"currently assessing the dataset and, assuming results remain favorable, intends to initiate the next stage of the clinical program.\" This is a material clinical development milestone for a clinical-stage biotech company, but it is not a discrete earnings release (no financial results disclosed), nor does it fit other specific event categories. It represents a significant operational/clinical progress event that would affect a reasonable investor's assessment of the company's pipeline advancement.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T12:09:07.603399+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":9519,"accession_number":"0001213900-26-070380","item_number":"EX-99.1","item_title":"ea029542902ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces the successful completion of Part A treatment for all 24 participants in Clearmind's Phase I/II clinical trial of CMND-100 for Alcohol Use Disorder. The company states it is \"currently assessing the dataset and, assuming results remain favorable, intends to initiate the next stage of the clinical program.\" This is a material clinical development milestone for a clinical-stage biotech company, but it is not a discrete earnings release (no financial results disclosed), nor does it fit other specific event categories. It represents a significant operational/clinical progress event that would affect a reasonable investor's assessment of the company's pipeline advancement.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T12:09:07.603399+00:00","company_name":"Clearmind Medicine Inc.","ticker":"CMND","filing_date":"2026-06-22"}]}